



Dear Angelman Syndrome Community,

As the COVID-19 pandemic evolves, our main concerns are you and your health. While we continue to focus on advancing our programs which includes planning for the phase 1/2 study in Angelman Syndrome patients, we are cognizant of the strain this pandemic puts on our healthcare systems.

Ionis is carefully monitoring the situation and focused on the safety of our study participants. For patients already enrolled in clinical trials, we advise patients and families participating in our clinical studies to follow the advice provided by their clinical trial site team and abide by any guidance issued by local authorities. For our upcoming clinical trial in AS, our priority is to keep the program on track and maintain our current timeline to start the study in the fall, while maintaining the safety of everyone involved.

Our plan is to keep you informed on our progress through community statements, such as this, and webinars and provide clear information about our clinical trial timelines.

We are confident that the actions we are taking will prevent undue burden on our healthcare systems, help protect the safety of patients, healthcare workers and employees, and maintain the quality of our studies and their timelines.

At Ionis, we know that the patient community depends on us and we are committed to continue our work on behalf of the patients we serve in the face of this global pandemic. We thank you for your patience and understanding.

We are in this together and we will get through this together.

With



The Ionis Team